Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
ZyVersa's mission is to develop novel, first-in-class drugs that optimize health outcomes and improve patients' quality of life. Our evolving product pipeline is targeted at renal and anti-inflammatory diseases.
* Orphan renal diseases
Our lead renal candidate is VAR 200, 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), a cholesterol efflux mediator for focal segmental glomerulosclerosis (FSGS). Based on preclinical studies, VAR 200 promotes active and passive cholesterol removal from podocytes, the kidney's filtering system, slowing progression of podocyte injury and renal disease.
Our lead anti-inflammatory drug candidate is IC 100, a novel inflammasome inhibitor targeting the upstream innate immune system. It inhibits the ASC component of inflammasomes to block intracellular initiation of the inflammatory cascade and extracellular perpetuation of inflammation. It has potential for multiple inflammatory conditions.